Novo's Oral Semaglutide Passes PIONEER 2, But Weight Loss Result A Bit Disappointing

In second Phase III diabetes study to report, oral GLP-1 agonist semaglutide misses some weight loss goals when compared with Boehringer/Lilly's SGLT-2 inhibitor Jardiance.